Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
J Org Chem ; 89(11): 8157-8167, 2024 Jun 07.
Artigo em Inglês | MEDLINE | ID: mdl-38727022

RESUMO

Direct transformations of diarylketones to hetero- and carbofunctionalized diarylmethanes have been developed. The reactions involve a phospha-Brook rearrangement of diphenylphosphine oxide with diarylketones, followed by substitutions with various nucleophiles such as amides, amines, phenols, thiols, and diborylmethane under palladium catalysis to afford the corresponding functionalized diarylmethanes in a reductive manner.

2.
Sci Rep ; 10(1): 11996, 2020 07 20.
Artigo em Inglês | MEDLINE | ID: mdl-32686737

RESUMO

α7 nicotinic acetylcholine receptors (nAChRs) are widely expressed in the central nervous system and regarded as potential therapeutic targets for neurodegenerative conditions, such as Alzheimer's disease and schizophrenia. Yet, despite the assumed pathophysiological importance of the α7 nAChR, molecular physiological characterization remains poorly advanced because α7 nAChR cannot be properly folded and sorted to the plasma membranes in most mammalian cell lines, thus preventing the analyses in heterologous expression system. Recently, ER-resident membrane protein NACHO was discovered as a strong chaperone for the functional expression of α7 nAChR in non-permissive cells. Ly6H, a brain-enriched GPI-anchored neurotoxin-like protein, was reported as a novel modulator regulating intracellular trafficking of α7 nAChR. In this study, we established cell lines that stably and robustly express surface α7 nAChR by introducing α7 nAChR, Ric-3, and NACHO cDNA into HEK293 cells (Triple α7 nAChR/RIC-3/NACHO cells; TARO cells), and re-evaluated the function of Ly6H. We report here that Ly6H binds with α7 nAChRs on the cell membrane and modulates the channel activity without affecting intracellular trafficking of α7 nAChR.


Assuntos
Membrana Celular/metabolismo , Ativação do Canal Iônico , Glicoproteínas de Membrana/metabolismo , Receptor Nicotínico de Acetilcolina alfa7/metabolismo , Animais , Membrana Celular/efeitos dos fármacos , Galinhas , Colina/farmacologia , Células HEK293 , Humanos , Ativação do Canal Iônico/efeitos dos fármacos , Proteínas Mutantes/metabolismo , Fosfoinositídeo Fosfolipase C/metabolismo , Ligação Proteica/efeitos dos fármacos , Solubilidade
3.
Sci Rep ; 6: 27354, 2016 06 06.
Artigo em Inglês | MEDLINE | ID: mdl-27264390

RESUMO

Differential vulnerability among motor neuron (MN) subtypes is a fundamental feature of amyotrophic lateral sclerosis (ALS): fast-fatigable (FF) MNs are more vulnerable than fast fatigue-resistant (FR) or slow (S) MNs. The reason for this selective vulnerability remains enigmatic. We report here that the extracellular matrix (ECM) protein osteopontin (OPN) is selectively expressed by FR and S MNs and ALS-resistant motor pools, whereas matrix metalloproteinase-9 (MMP-9) is selectively expressed by FF MNs. OPN is secreted and accumulated as extracellular granules in ECM in three ALS mouse models and a human ALS patient. In SOD1(G93A) mice, OPN/MMP-9 double positivity marks remodeled FR and S MNs destined to compensate for lost FF MNs before ultimately dying. Genetic ablation of OPN in SOD1(G93A) mice delayed disease onset but then accelerated disease progression. OPN induced MMP-9 up-regulation via αvß3 integrin in ChAT-expressing Neuro2a cells, and also induced CD44-mediated astrocyte migration and microglial phagocytosis in a non-cell-autonomous manner. Our results demonstrate that OPN expressed by FR/S MNs is involved in the second-wave neurodegeneration by up-regulating MMP-9 through αvß3 integrin in the mouse model of ALS. The differences in OPN/MMP-9 expression profiles in MN subsets partially explain the selective MN vulnerability in ALS.


Assuntos
Esclerose Lateral Amiotrófica/fisiopatologia , Integrina alfaVbeta3/metabolismo , Metaloproteinase 9 da Matriz/metabolismo , Neurônios Motores/fisiologia , Osteopontina/metabolismo , Animais , Modelos Animais de Doenças , Humanos , Camundongos
4.
Int J Mol Med ; 12(2): 185-91, 2003 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-12851715

RESUMO

We identified a novel heterozygous single-nucleotide substitution 1400 T right curved arrow C (Leu 467 Pro) in the seventh exon of the interferon-gamma receptor 1 (IFNGR1) gene. This substitution was detected in 6 of the 89 allergic patients but not in the 72 non-allergic subjects. There was a difference in the L467P frequency between the allergic patients and the non-allergic subjects (Fisher's exact test: p=0.033). The 6 patients with L467P have allergic diseases such as bronchial asthma and/or allergic rhinitis. Furthermore, a familial analysis for L467P revealed a linkage between allergic diseases and L467P. Serum IgE levels of the patients with L467P were higher than those of the non-allergic subjects (p=0.001). Our previous studies have been shown that interferon-gamma (IFN-gamma) production by PBMCs in the allergic patients was lower than that in the non-allergic subjects. In this study, although IFN-gamma production in the allergic patients with L467P was equivalent to that in the non-allergic subjects, their serum IgE levels were high and they had allergic diseases. Our results suggest that some allergic patients have IFNGR dysfunction, and that L467P in the IFNGR1 gene is one of candidate susceptibility genes for allergic diseases.


Assuntos
Substituição de Aminoácidos , Hipersensibilidade/genética , Mutação Puntual , Receptores de Interferon/genética , Adolescente , Adulto , Asma/genética , Estudos de Casos e Controles , Células Cultivadas , Criança , Proteínas de Ligação a DNA/metabolismo , Dermatite Atópica/genética , Feminino , Ligação Genética , Predisposição Genética para Doença , Humanos , Imunoglobulina E/sangue , Interferon gama/metabolismo , Interleucina-12/farmacologia , Interleucina-18/farmacologia , Leucina/genética , Masculino , Neutrófilos/efeitos dos fármacos , Neutrófilos/metabolismo , Linhagem , Fosforilação , Prolina/genética , Rinite Alérgica Perene/genética , Fator de Transcrição STAT1 , Transativadores/metabolismo , Receptor de Interferon gama
6.
Arerugi ; 51(5): 421-9, 2002 May.
Artigo em Japonês | MEDLINE | ID: mdl-12087760

RESUMO

We conducted a longitudinal investigation with the QOL questionnaire (revised version 2001) before and after the 4-week-administration of a leukotriene receptor antagonist pranlukast. A significant improvement in the < 4 yrs group was observed at week 1, and that in > or = 4 yrs group at week 2. Under these conditions, the overall QOL score, physical domains and mental domains, significantly improved in both the < 4 yrs group and the > or = 4 yrs group. Overall, a slight correlation was observed between ratio changes in QOL scores and differences in symptom scores. However, no correlation was found in part of patients, suggesting that the QOL questionnaire allows measurement of mental changes in the patients themselves and their parents or caregivers for therapeutic effects which cannot be determined with ordinary physical findings only. In "event present" group, a significant difference in physical and mental domains was revealed by the comparison of QOL scores before and after administration. And furthermore in "event absence" group, the p-value for physical domain and mental domain was 0.0505 and 0.0912 in the < 4 yrs group, respectively, 0.0101 and 0.0446 in the > or = 4 yrs group, respectively. The above results led us to consider the QOL questionnaire (revised version 2001) useful for routine medical care. Furthermore, pranlukast was considered useful for improvement not only of physical symptoms of bronchial asthma but also of the patient's QOL, although the placebo effects in this open trial must be considered.


Assuntos
Antiasmáticos/uso terapêutico , Asma/tratamento farmacológico , Cromonas/uso terapêutico , Antagonistas de Leucotrienos/uso terapêutico , Qualidade de Vida , Pré-Escolar , Feminino , Humanos , Estudos Longitudinais , Masculino , Inquéritos e Questionários
7.
J Allergy Clin Immunol ; 109(4): 669-75, 2002 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-11941317

RESUMO

BACKGROUND: We previously reported that serum IgE levels were negatively correlated with the amount of IFN-gamma produced by phytohemagglutinin-stimulated or IL-12-stimulated PBMCs and that one of the mechanisms of the pathogenesis of atopy was the reduced IFN-gamma production, which led to upregulated IgE production. OBJECTIVE: IL-18 is also known to be a strong inducer of IFN-gamma production. However, it has not yet been determined whether IL-18 is associated with atopic disease. METHODS: We investigated the response to IL-18 or IL-12 stimulation and the sequence of IL-18 receptor (IL-18R) alpha chain cDNA in 41 nonatopic controls and 39 atopic patients. RESULTS: Serum IgE level was negatively correlated with IFN-gamma production by PBMCs stimulated with IL-18. The IL-18R alpha chain cDNA of atopic patients was sequenced. We identified a 3-base deletion of the IL-18R alpha chain cDNA (950delCAG ), which was generated by alternative splicing, as determined on the basis of genomic sequence data for the IL-18R alpha chain gene. PBMCs with the predominant expression of 950delCAG significantly showed the reduced IFN-gamma production after IL-18 stimulation. There was a significant difference in the expression pattern of the IL-18R alpha chain transcript between the atopic patients and the nonatopic controls. CONCLUSION: According to these results, the dominant expression of the 950delCAG transcript of IL-18R alpha chain cDNA, which was associated with reduced IFN-gamma production by IL-18 stimulation and high serum IgE levels, is predisposition to some atopic diseases.


Assuntos
DNA Complementar/análise , Deleção de Genes , Hipersensibilidade/imunologia , Imunoglobulina E/sangue , Interferon gama/biossíntese , Receptores de Interleucina/genética , Adolescente , Células Cultivadas , Criança , Pré-Escolar , Humanos , Hipersensibilidade/genética , Lactente , Interleucina-18/farmacologia , Subunidade alfa de Receptor de Interleucina-18 , Fito-Hemaglutininas/farmacologia , RNA Mensageiro/análise , Receptores de Interleucina-18
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA